50-264-3310
P16INK4a Recombinant Mouse Monoclonal Antibody (rCDKN2A/8062), NeoBiotechnologies™
Manufacturer: Fischer Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | 50-264-3310-Each-of-1 | In Stock | ₹ 55,340.21 |
50-264-3310 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 55,340.21
GST (18%): ₹ 9,961.238
Total Price: ₹ 65,301.448
Antigen
P16INK4a
Classification
Recombinant Monoclonal
Concentration
200 μg/mL
Formulation
PBS with 0.5% BSA and 0.5% sodium azide
Gene Accession No.
P42771
Host Species
Mouse
Purification Method
Protein A/G
Regulatory Status
RUO
Gene ID (Entrez)
1029
Content And Storage
4° C
Form
Liquid
Applications
Immunohistochemistry (Paraffin)
Clone
rCDKN2A/8062
Conjugate
Unconjugated
Gene
CDKN2A
Gene Alias
Alternative reading frame; Arf; ARF-INK4a; CDK4 inhibitor p16 INK4; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; Cyclin dependent kinase 4 inhibitor A; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; HGNC:1787; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; isoforms 1/2/3; Melanoma p16 inhibits CDK4; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; P14 P16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; p16INK4a; p16-INK4a; P19; P19 TP16; p19<ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen
Recombinant fragment (around aa1-100) of human CDKN2A protein (exact sequence is proprietary)
Quantity
100 μg
Primary or Secondary
Primary
Target Species
Human
Product Type
Antibody
Isotype
IgG1 κ
Related Products
Description
- Positive Control:Human cervical squamous cell carcinoma
- Cellular Location: Nucleus
- Cytoplasm
- P16INK4a Recombinant Monoclonal antibody specifically detects P16INK4a in Human samples
- It is validated for Immunohistochemistry (Paraffin)
Compare Similar Items
Show Difference
Antigen: P16INK4a
Classification: Recombinant Monoclonal
Concentration: 200 μg/mL
Formulation: PBS with 0.5% BSA and 0.5% sodium azide
Gene Accession No.: P42771
Host Species: Mouse
Purification Method: Protein A/G
Regulatory Status: RUO
Gene ID (Entrez): 1029
Content And Storage: 4° C
Form: Liquid
Applications: Immunohistochemistry (Paraffin)
Clone: rCDKN2A/8062
Conjugate: Unconjugated
Gene: CDKN2A
Gene Alias: Alternative reading frame; Arf; ARF-INK4a; CDK4 inhibitor p16 INK4; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; Cyclin dependent kinase 4 inhibitor A; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; HGNC:1787; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; isoforms 1/2/3; Melanoma p16 inhibits CDK4; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; P14 P16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; p16INK4a; p16-INK4a; P19; P19 TP16; p19<ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen: Recombinant fragment (around aa1-100) of human CDKN2A protein (exact sequence is proprietary)
Quantity: 100 μg
Primary or Secondary: Primary
Target Species: Human
Product Type: Antibody
Isotype: IgG1 κ
Antigen:
P16INK4a
Classification:
Recombinant Monoclonal
Concentration:
200 μg/mL
Formulation:
PBS with 0.5% BSA and 0.5% sodium azide
Gene Accession No.:
P42771
Host Species:
Mouse
Purification Method:
Protein A/G
Regulatory Status:
RUO
Gene ID (Entrez):
1029
Content And Storage:
4° C
Form:
Liquid
Applications:
Immunohistochemistry (Paraffin)
Clone:
rCDKN2A/8062
Conjugate:
Unconjugated
Gene:
CDKN2A
Gene Alias:
Alternative reading frame; Arf; ARF-INK4a; CDK4 inhibitor p16 INK4; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; Cyclin dependent kinase 4 inhibitor A; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; HGNC:1787; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; isoforms 1/2/3; Melanoma p16 inhibits CDK4; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; P14 P16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; p16INK4a; p16-INK4a; P19; P19 TP16; p19<ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen:
Recombinant fragment (around aa1-100) of human CDKN2A protein (exact sequence is proprietary)
Quantity:
100 μg
Primary or Secondary:
Primary
Target Species:
Human
Product Type:
Antibody
Isotype:
IgG1 κ
Antigen: P16INK4a
Classification: Recombinant Monoclonal
Concentration: 200 μg/mL
Formulation: PBS with 0.5% BSA and 0.5% sodium azide
Gene Accession No.: P42771
Host Species: Mouse
Purification Method: Protein A/G
Regulatory Status: RUO
Gene ID (Entrez): 1029
Content And Storage: 4° C
Form: Liquid
Applications: Immunohistochemistry (Paraffin)
Clone: rCDKN2A/8062
Conjugate: Unconjugated
Gene: CDKN2A
Gene Alias: Alternative reading frame; Arf; ARF-INK4a; CDK4 inhibitor p16 INK4; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; Cyclin dependent kinase 4 inhibitor A; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; HGNC:1787; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; isoforms 1/2/3; Melanoma p16 inhibits CDK4; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; P14 P16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; p16INK4a; p16-INK4a; P19; P19 TP16; p19<ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen: Recombinant fragment (around aa1-100) of human CDKN2A protein (exact sequence is proprietary)
Quantity: 20 μg
Primary or Secondary: Primary
Target Species: Human
Product Type: Antibody
Isotype: IgG1 κ
Antigen:
P16INK4a
Classification:
Recombinant Monoclonal
Concentration:
200 μg/mL
Formulation:
PBS with 0.5% BSA and 0.5% sodium azide
Gene Accession No.:
P42771
Host Species:
Mouse
Purification Method:
Protein A/G
Regulatory Status:
RUO
Gene ID (Entrez):
1029
Content And Storage:
4° C
Form:
Liquid
Applications:
Immunohistochemistry (Paraffin)
Clone:
rCDKN2A/8062
Conjugate:
Unconjugated
Gene:
CDKN2A
Gene Alias:
Alternative reading frame; Arf; ARF-INK4a; CDK4 inhibitor p16 INK4; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; Cyclin dependent kinase 4 inhibitor A; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; HGNC:1787; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; isoforms 1/2/3; Melanoma p16 inhibits CDK4; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; P14 P16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; p16INK4a; p16-INK4a; P19; P19 TP16; p19<ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen:
Recombinant fragment (around aa1-100) of human CDKN2A protein (exact sequence is proprietary)
Quantity:
20 μg
Primary or Secondary:
Primary
Target Species:
Human
Product Type:
Antibody
Isotype:
IgG1 κ
Antigen: P16INK4a
Classification: Recombinant Monoclonal
Concentration: 200 μg/mL
Formulation: PBS with 0.5% BSA and 0.5% sodium azide
Gene Accession No.: P42771
Host Species: Mouse
Purification Method: Protein A/G
Regulatory Status: RUO
Gene ID (Entrez): 1029
Content And Storage: 4° C
Form: Liquid
Applications: Immunohistochemistry (Paraffin)
Clone: rCDKN2A/8061
Conjugate: Unconjugated
Gene: CDKN2A
Gene Alias: Alternative reading frame; Arf; ARF-INK4a; CDK4 inhibitor p16 INK4; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; Cyclin dependent kinase 4 inhibitor A; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; HGNC:1787; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; isoforms 1/2/3; Melanoma p16 inhibits CDK4; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; P14 P16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; p16INK4a; p16-INK4a; P19; P19 TP16; p19<ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen: Recombinant fragment (around aa1-100) of human CDKN2A protein (exact sequence is proprietary)
Quantity: 100 μg
Primary or Secondary: Primary
Target Species: Human
Product Type: Antibody
Isotype: IgG1 κ
Antigen:
P16INK4a
Classification:
Recombinant Monoclonal
Concentration:
200 μg/mL
Formulation:
PBS with 0.5% BSA and 0.5% sodium azide
Gene Accession No.:
P42771
Host Species:
Mouse
Purification Method:
Protein A/G
Regulatory Status:
RUO
Gene ID (Entrez):
1029
Content And Storage:
4° C
Form:
Liquid
Applications:
Immunohistochemistry (Paraffin)
Clone:
rCDKN2A/8061
Conjugate:
Unconjugated
Gene:
CDKN2A
Gene Alias:
Alternative reading frame; Arf; ARF-INK4a; CDK4 inhibitor p16 INK4; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; Cyclin dependent kinase 4 inhibitor A; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; HGNC:1787; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; isoforms 1/2/3; Melanoma p16 inhibits CDK4; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; P14 P16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; p16INK4a; p16-INK4a; P19; P19 TP16; p19<ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen:
Recombinant fragment (around aa1-100) of human CDKN2A protein (exact sequence is proprietary)
Quantity:
100 μg
Primary or Secondary:
Primary
Target Species:
Human
Product Type:
Antibody
Isotype:
IgG1 κ
Antigen: P16INK4a
Classification: Recombinant Monoclonal
Concentration: 200 μg/mL
Formulation: PBS with 0.5% BSA and 0.5% sodium azide
Gene Accession No.: P42771
Host Species: Mouse
Purification Method: Protein A/G
Regulatory Status: RUO
Gene ID (Entrez): 1029
Content And Storage: 4° C
Form: Liquid
Applications: Immunohistochemistry (Paraffin)
Clone: rCDKN2A/8061
Conjugate: Unconjugated
Gene: CDKN2A
Gene Alias: Alternative reading frame; Arf; ARF-INK4a; CDK4 inhibitor p16 INK4; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; Cyclin dependent kinase 4 inhibitor A; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; HGNC:1787; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; isoforms 1/2/3; Melanoma p16 inhibits CDK4; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; P14 P16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; p16INK4a; p16-INK4a; P19; P19 TP16; p19<ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen: Recombinant fragment (around aa1-100) of human CDKN2A protein (exact sequence is proprietary)
Quantity: 20 μg
Primary or Secondary: Primary
Target Species: Human
Product Type: Antibody
Isotype: IgG1 κ
Antigen:
P16INK4a
Classification:
Recombinant Monoclonal
Concentration:
200 μg/mL
Formulation:
PBS with 0.5% BSA and 0.5% sodium azide
Gene Accession No.:
P42771
Host Species:
Mouse
Purification Method:
Protein A/G
Regulatory Status:
RUO
Gene ID (Entrez):
1029
Content And Storage:
4° C
Form:
Liquid
Applications:
Immunohistochemistry (Paraffin)
Clone:
rCDKN2A/8061
Conjugate:
Unconjugated
Gene:
CDKN2A
Gene Alias:
Alternative reading frame; Arf; ARF-INK4a; CDK4 inhibitor p16 INK4; CDK4 inhibitor p16-INK4; CDK4I; CDKN2; Cdkn2a; cdkn2a {ECO:0000312; cell cycle inhibitor; cell cycle negative regulator beta; cell cycle regulator; CMM2; Cyclin dependent kinase 4 inhibitor A; cyclin dependent kinase inhibitor 2A; Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase 4 inhibitor A; Cyclin-dependent kinase inhibitor 2A; cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2a p16Ink4a; cyclin-dependent kinase inhibitor 2a p19Arf; cyclin-dependent kinase inhibitor 2A, isoform 1; cyclin-dependent kinase inhibitor 2A, isoform 2; cyclin-dependent kinase inhibitor 2A, isoform 3; cyclin-dependent kinase inhibitor 2A, isoforms 1/2; cyclin-dependent kinase inhibitor protein; EMBL:AAL76336.1, ECO:0000312; EMBL:AAL76338.1, ECO:0000312; HGNC:1787; inhibits CDK4; INK4; INK4A; Ink4a/Arf; INK4a-ARF; isoforms 1/2/3; Melanoma p16 inhibits CDK4; mitochondrial smARF; MLM; MTS1; MTS-1; Multiple tumor suppressor 1; P14; P14 P16; P14ARF; p16; p16(INK4a); p16Cdkn2a; P16INK4; p16-INK4; p16INK4a; p16-INK4a; P19; P19 TP16; p19<ARF>; P19ARF; Pctr1; RGD:2323}; TP16; Tumor suppressor ARF
Immunogen:
Recombinant fragment (around aa1-100) of human CDKN2A protein (exact sequence is proprietary)
Quantity:
20 μg
Primary or Secondary:
Primary
Target Species:
Human
Product Type:
Antibody
Isotype:
IgG1 κ